# D9319C00001- 1L OC Mono Global RCT

Source: https://onco.cc/trials/nct04884360/  
OnCo record `nct04884360` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Olaparib in ovarian cancer, run by AstraZeneca, active and no longer recruiting.

## Summary

D9319C00001- 1L OC Mono Global RCT is a phase 3 interventional study registered as NCT04884360 by AstraZeneca, with 366 participants enrolled, started 2021-05-31 and due to reach its primary completion in 2026-07-27. Interventions recorded: Olaparib, Matching placebo. Conditions listed: Ovarian Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04884360
- Phase: 3
- Setting: A Randomised, Double-blind, Placebo-controlled, Phase III Study of Olaparib Maintenance Monotherapy in Participants With BRCA Wild Type Advanced High Grade Serous or Endometrioid Ovarian Cancer Following Response to Standard First-line Platinum-based Chemotherapy (MONO-OLA1)
- Sponsor: AstraZeneca
- Enrolled: 366

## Sources

- ClinicalTrials.gov NCT04884360: https://clinicaltrials.gov/study/NCT04884360

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [Olaparib](https://onco.cc/drugs/olaparib/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct04884360.json